Marker Therapeutics, Inc. financial data

Symbol
MRKR on Nasdaq
Industry
Pharmaceutical Preparations
Location
2450 Holcombe Blvd, Suite Bcm A, Ms: Bcm251, Houston, TX
State of incorporation
DE
Fiscal year end
December 31
Former names
TAPIMMUNE INC. (to 10/17/2018), TAPIMMUNE INC (to 6/29/2017), GENEMAX CORP (to 6/28/2007), EDUVERSE COM (to 6/17/2002)
Latest financial report
10-Q - Q3 2024 - Nov 14, 2024

Key Ratios

Label TTM Value / Value Unit Change %
Current Ratio 498 % +34.8%
Debt-to-equity 25.2 % -44.9%
Return On Equity -90.2 % -73%
Return On Assets -72.1 % -101%

Shares

Label TTM Value / Value Unit Change %
Entity Common Stock, Shares Outstanding 8.92M shares +0.39%
Common Stock, Shares, Outstanding 8.9M shares +1.14%
Entity Public Float 23.1M USD +1.32%
Common Stock, Value, Issued 8.92K USD +0.39%
Weighted Average Number of Shares Outstanding, Basic 8.92M shares +1.1%
Weighted Average Number of Shares Outstanding, Diluted 8.92M shares +1.1%

Income Statement

Label TTM Value / Value Unit Change %
Research and Development Expense 11M USD +76.7%
General and Administrative Expense 4.59M USD -37.4%
Operating Income (Loss) -10.2M USD +3.32%
Net Income (Loss) Attributable to Parent -9.7M USD -4.38%
Earnings Per Share, Basic -1.1 USD/shares -2.8%
Earnings Per Share, Diluted -1.1 USD/shares -2.8%

Balance Sheet

Label TTM Value / Value Unit Change %
Cash and Cash Equivalents, at Carrying Value 9M USD -48.5%
Assets, Current 10.9M USD -44%
Property, Plant and Equipment, Net 11.7M USD -18.5%
Operating Lease, Right-of-Use Asset 5.33M USD -44.4%
Assets 10.9M USD -44%
Accounts Payable, Current 1.9M USD +63.4%
Employee-related Liabilities, Current 39K USD -45.1%
Liabilities, Current 3.46M USD +24.5%
Operating Lease, Liability, Noncurrent 6.82M USD -38.2%
Liabilities 3.46M USD +24.5%
Retained Earnings (Accumulated Deficit) -443M USD -2.24%
Stockholders' Equity Attributable to Parent 7.45M USD -55.4%
Liabilities and Equity 10.9M USD -44%

Popular Metrics

Label TTM Value / Value Unit Change %
Net Cash Provided by (Used in) Operating Activities -3.84M USD +34.8%
Net Cash Provided by (Used in) Financing Activities 49.1K USD -92.1%
Net Cash Provided by (Used in) Investing Activities -113K USD +95.4%
Common Stock, Shares Authorized 30M shares 0%
Common Stock, Shares, Issued 8.9M shares +1.14%
Common Stock, Par or Stated Value Per Share 0 USD/shares 0%
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect 28.8M USD
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents 9M USD -48.5%
Deferred Tax Assets, Valuation Allowance 39.7M USD -3.77%
Deferred Tax Assets, Gross 39.7M USD -3.77%
Operating Lease, Liability 7.49M USD -36.1%
Depreciation 800K USD -63.6%
Lessee, Operating Lease, Liability, to be Paid 9.23M USD -38.4%
Property, Plant and Equipment, Gross 17.8M USD +30.9%
Operating Lease, Liability, Current 665K USD -2.76%
Lessee, Operating Lease, Liability, to be Paid, Year Two 1.29M USD -16.3%
Lessee, Operating Lease, Liability, to be Paid, Year One 1.25M USD +30.5%
Operating Lease, Weighted Average Discount Rate, Percent 0.06 pure 0%
Lessee, Operating Lease, Liability, Undiscounted Excess Amount 1.74M USD -46.7%
Lessee, Operating Lease, Liability, to be Paid, Year Three 1.18M USD -35.5%
Deferred Tax Assets, Operating Loss Carryforwards 29.4M USD -2.39%
Preferred Stock, Shares Issued 0 shares
Preferred Stock, Shares Authorized 5M shares 0%
Unrecognized Tax Benefits 0 USD
Lessee, Operating Lease, Liability, to be Paid, Year Four 1.16M USD -37.9%
Operating Lease, Payments 232K USD -26.6%
Additional Paid in Capital 451M USD +0.1%
Preferred Stock, Shares Outstanding 0 shares
Depreciation, Depletion and Amortization 818K USD +42%
Deferred Tax Assets, Net of Valuation Allowance 1.46M USD -32.8%
Share-based Payment Arrangement, Expense 337K USD -84.4%
Preferred Stock, Par or Stated Value Per Share 0 USD/shares 0%